University of Virginia’s (UVA) Center for Diabetes Technology (CDT) has licensed Klue’s gesture sensing and behavioural analytics software for a proposed clinical trial to further diabetes treatment.
Klue is currently developing an operating system for behaviour change and real-time digital therapeutics.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The UVA CDT is planning to advance technology use, including the development of decision support and automated insulin delivery systems. This is intended to bring about improvement in the management, monitoring, and therapies for patients with Type 1 Diabetes.
CDT will validate Klue’s mealtime insulin reminder application in a randomised clinical trial for a period of 12 weeks.
The study has secured approval from the Institutional Review Board (IRB) and is currently enrolling patients.
Klue founder and CEO Katelijn Vleugels said: “We are thrilled to be working with the team at the UVA Center for Diabetes Technology to accelerate diabetes technologies research and study how our software can reduce the burden for individuals with diabetes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our collaboration underscores how automatic meal signalling may very well transform the future of diabetes care.”
With this clinical trial, the CDT and Klue aim to increase the scientific understanding of the way automatic meal detection can reduce the daily burden on Type 1 diabetes patients when combined with real-time signalling.
Klue’s motor artificial intelligence technology analyses the wrist movements of a user and is intended to reduce eating and drinking.
UVA Center for Diabetes Technology associate professor Dr Marc Breton said: “The study is intended to provide greater insight and further understand how real-time meal detection can be beneficial to people with Type 1 diabetes and their care providers.
“Technologies like Klue added to novel closed-loop insulin dosing algorithms could get us closer to the advanced autonomous systems patients have been asking for.”
